BioHarvest Sciences (BHST)
Market Price (9/5/2026): $1.79 | Market Cap: $40.6 MilSector: Consumer Staples | Industry: Packaged Foods & Meats
BioHarvest Sciences (BHST)
Market Price (9/5/2026): $1.79Market Cap: $40.6 MilSector: Consumer StaplesIndustry: Packaged Foods & Meats
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 18% Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -58% Megatrend and thematic driversMegatrends include Health & Wellness Trends, and Vegan & Alternative Foods. Themes include Nutritional Supplements, Vegan Products, Show more. | Weak multi-year price returns2Y Excs Rtn is -103%, 3Y Excs Rtn is -132% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -6.4 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -18% Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -24%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -30% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -31% Key risksBHST key risks include [1] its continued unprofitability and reliance on potentially dilutive external financing, Show more. |
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 18% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -58% |
| Megatrend and thematic driversMegatrends include Health & Wellness Trends, and Vegan & Alternative Foods. Themes include Nutritional Supplements, Vegan Products, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -103%, 3Y Excs Rtn is -132% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -6.4 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -18% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -24%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -30% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -31% |
| Key risksBHST key risks include [1] its continued unprofitability and reliance on potentially dilutive external financing, Show more. |
Qualitative Assessment
AI Analysis | Feedback
BioHarvest Sciences (BHST) stock has lost about 55% since 5/31/2026 because of the following key factors:
1. BioHarvest Sciences (BHST) missed analyst expectations for fiscal Q2 2026 (ended June 30, 2026) earnings and revenue, leading to a significant reduction in full-year guidance. The company reported an EPS of -$0.17, missing the consensus estimate of -$0.13 by $0.04. Quarterly revenue came in at $8.84 million, falling short of the $9.45 million consensus estimate. Following these results, BioHarvest Sciences cut its full-year 2026 revenue guidance for its VINIA direct-to-consumer (D2C) business from an initial $38-$42 million to $33-$35 million. Furthermore, the consolidated 2026 EBITDA loss guidance widened from $3-$4 million to $3-$5 million. This downward revision in financial projections signaled a weaker near-term outlook than previously anticipated by the market.
2. The company disclosed "substantial doubt" about its ability to continue as a going concern due to recurring losses and the need for continued investment. In its H1 2026 report, released in conjunction with the fiscal Q2 2026 results on August 11, 2026, BioHarvest Sciences stated that ongoing operating and cash losses, coupled with the uncertainty of raising additional capital, "raise substantial doubt" about its ability to maintain operations, despite current liquidity. For H1 2026, the company recorded an operating loss of $4.341 million and utilized $4.170 million in net cash from operating activities, highlighting its non-self-funding status.
Show more
BioHarvest Sciences (BHST) stock has lost about 55% since 5/31/2026 because of the following key factors:
1. BioHarvest Sciences (BHST) missed analyst expectations for fiscal Q2 2026 (ended June 30, 2026) earnings and revenue, leading to a significant reduction in full-year guidance. The company reported an EPS of -$0.17, missing the consensus estimate of -$0.13 by $0.04. Quarterly revenue came in at $8.84 million, falling short of the $9.45 million consensus estimate. Following these results, BioHarvest Sciences cut its full-year 2026 revenue guidance for its VINIA direct-to-consumer (D2C) business from an initial $38-$42 million to $33-$35 million. Furthermore, the consolidated 2026 EBITDA loss guidance widened from $3-$4 million to $3-$5 million. This downward revision in financial projections signaled a weaker near-term outlook than previously anticipated by the market.
2. The company disclosed "substantial doubt" about its ability to continue as a going concern due to recurring losses and the need for continued investment. In its H1 2026 report, released in conjunction with the fiscal Q2 2026 results on August 11, 2026, BioHarvest Sciences stated that ongoing operating and cash losses, coupled with the uncertainty of raising additional capital, "raise substantial doubt" about its ability to maintain operations, despite current liquidity. For H1 2026, the company recorded an operating loss of $4.341 million and utilized $4.170 million in net cash from operating activities, highlighting its non-self-funding status.
3. Increased operating expenses and a strategic shift towards longer-term revenue generation from its CDMO business impacted near-term profitability. BioHarvest Sciences' operating expenses increased to $7.6 million in fiscal Q2 2026, up from $6.9 million in the same period a year prior, driven by higher sales and marketing spending and increased research and development efforts. While the company secured its first major Contract Development and Manufacturing Organization (CDMO) agreement for a rare botanical fragrance on August 11, 2026, which is expected to generate $20-$30 million in revenue between 2027 and 2028, production for this is not anticipated until the first half of 2027. This strategic reallocation of spending from the VINIA D2C business toward CDMO manufacturing capacity and investments is projected to delay more substantial revenue contributions and impact near-term financial performance.
Show less
Stock Movement Drivers
Fundamental Drivers
The -52.8% change in BHST stock from 5/31/2026 to 9/4/2026 was primarily driven by a -53.3% change in the company's P/S Multiple.| (LTM values as of) | 5312026 | 9042026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.86 | 1.82 | -52.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 35 | 35 | 0.9% |
| P/S Multiple | 2.5 | 1.2 | -53.3% |
| Shares Outstanding (Mil) | 23 | 23 | 0.0% |
| Cumulative Contribution | -52.8% |
Market Drivers
5/31/2026 to 9/4/2026| Return | Correlation | |
|---|---|---|
| BHST | -52.8% | |
| Market (SPY) | 1.8% | -0.2% |
| Sector (XLP) | 2.0% | 13.9% |
Fundamental Drivers
The -61.4% change in BHST stock from 2/28/2026 to 9/4/2026 was primarily driven by a -53.6% change in the company's P/S Multiple.| (LTM values as of) | 2282026 | 9042026 | Change |
|---|---|---|---|
| Stock Price ($) | 4.71 | 1.82 | -61.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 33 | 35 | 8.4% |
| P/S Multiple | 2.5 | 1.2 | -53.6% |
| Shares Outstanding (Mil) | 17 | 23 | -23.1% |
| Cumulative Contribution | -61.4% |
Market Drivers
2/28/2026 to 9/4/2026| Return | Correlation | |
|---|---|---|
| BHST | -61.4% | |
| Market (SPY) | 12.6% | 6.9% |
| Sector (XLP) | -5.5% | 16.3% |
Fundamental Drivers
The -77.8% change in BHST stock from 8/31/2025 to 9/4/2026 was primarily driven by a -75.2% change in the company's P/S Multiple.| (LTM values as of) | 8312025 | 9042026 | Change |
|---|---|---|---|
| Stock Price ($) | 8.18 | 1.82 | -77.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 30 | 35 | 17.5% |
| P/S Multiple | 4.7 | 1.2 | -75.2% |
| Shares Outstanding (Mil) | 17 | 23 | -23.6% |
| Cumulative Contribution | -77.8% |
Market Drivers
8/31/2025 to 9/4/2026| Return | Correlation | |
|---|---|---|
| BHST | -77.8% | |
| Market (SPY) | 20.4% | 16.3% |
| Sector (XLP) | 6.9% | 2.6% |
Fundamental Drivers
The -60.0% change in BHST stock from 8/31/2023 to 9/4/2026 was primarily driven by a -83.1% change in the company's P/S Multiple.| (LTM values as of) | 8312023 | 9042026 | Change |
|---|---|---|---|
| Stock Price ($) | 4.55 | 1.82 | -60.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 9 | 35 | 299.8% |
| P/S Multiple | 6.9 | 1.2 | -83.1% |
| Shares Outstanding (Mil) | 13 | 23 | -40.8% |
| Cumulative Contribution | -60.0% |
Market Drivers
8/31/2023 to 9/4/2026| Return | Correlation | |
|---|---|---|
| BHST | -60.0% | |
| Market (SPY) | 77.1% | 14.2% |
| Sector (XLP) | 25.2% | 3.2% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| BHST Return | 100% | -39% | -28% | 12% | -16% | -65% | -71% |
| Peers Return | 8% | -67% | 26% | -10% | -22% | 43% | -56% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 13% | 106% |
Monthly Win Rates [3] | |||||||
| BHST Win Rate | 42% | 33% | 42% | 58% | 58% | 0% | |
| Peers Win Rate | 54% | 20% | 57% | 45% | 37% | 53% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 56% | |
Max Drawdowns [4] | |||||||
| BHST Max Drawdown | -59% | -59% | -49% | -39% | -60% | -69% | |
| Peers Max Drawdown | -38% | -70% | -50% | -51% | -53% | -44% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: DNA, CDXS, TWST, NATR, USNA.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 9/4/2026 (YTD)
How Low Can It Go
| Event | BHST | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -11.6% | -18.8% |
| % Gain to Breakeven | 13.2% | 23.1% |
| Time to Breakeven | 11 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -13.3% | -9.5% |
| % Gain to Breakeven | 15.4% | 10.5% |
| Time to Breakeven | 6 days | 24 days |
| 2020 COVID-19 Crash | ||
| % Loss | -56.1% | -33.7% |
| % Gain to Breakeven | 128.0% | 50.9% |
| Time to Breakeven | 254 days | 140 days |
In The Past
BioHarvest Sciences's stock fell -11.6% during the 2025 US Tariff Shock. Such a loss loss requires a 13.2% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | BHST | S&P 500 |
|---|---|---|
| 2020 COVID-19 Crash | ||
| % Loss | -56.1% | -33.7% |
| % Gain to Breakeven | 128.0% | 50.9% |
| Time to Breakeven | 254 days | 140 days |
In The Past
BioHarvest Sciences's stock fell -11.6% during the 2025 US Tariff Shock. Such a loss loss requires a 13.2% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About BioHarvest Sciences (BHST)
BioHarvest Sciences Inc. is a biotechnology company that leverages its proprietary botanical synthesis platform technology to grow plant-based ingredients, such as enzymes and cells, in a controlled environment. This innovative technology enables the company to develop science-backed therapeutic solutions across both the nutraceuticals and pharmaceuticals industries. Essentially, they cultivate specific plant compounds efficiently and consistently for various applications.
The company offers a range of products and services. A prominent consumer product is VINIA, a red grape cell dietary supplement designed to deliver the beneficial polyphenols found in red grapes. Beyond VINIA and other wellness products, BioHarvest Sciences also operates as a contract development and manufacturing organization (CDMO). Through its CDMO services, the company provides its botanical synthesis expertise and manufacturing capabilities to other businesses.
BioHarvest Sciences primarily serves two distinct customer bases. On one hand, it targets consumers seeking clinically proven, science-based wellness solutions, particularly with its direct-to-consumer offerings like VINIA. On the other hand, its CDMO segment caters to other companies within the biotechnology and pharmaceutical sectors that require specialized development and manufacturing services for plant-derived ingredients.
AI Analysis | Feedback
Here are 1-3 brief analogies for BioHarvest Sciences (BHST):
- Imagine Impossible Foods, but for lab-grown plant extracts and compounds used in health supplements and pharmaceuticals.
- They're like Moderna, applying a unique 'botanical synthesis' platform technology to create a range of plant-based ingredients for health supplements and drugs.
- Think of them as the Tesla for natural health ingredients, utilizing advanced biotech to produce specific plant compounds more consistently and sustainably.
AI Analysis | Feedback
- VINIA: A red grape cell dietary supplement containing a matrix of polyphenols designed for wellness.
- Therapeutic Solutions: Science-based and clinically proven solutions leveraging their botanical synthesis technology for both nutraceutical and pharmaceutical applications.
- Contract Development and Manufacturing Operation (CDMO) Services: Services provided to other companies for the development and manufacturing of products utilizing their botanical synthesis platform.
AI Analysis | Feedback
BioHarvest Sciences Inc. primarily sells its flagship product, VINIA, a red grape cell dietary supplement, directly to individual consumers through its e-commerce platforms. Based on this direct-to-consumer model for its main revenue-generating product, the major customer categories are:
- Health-Conscious Individuals: This category includes consumers who are proactive about their health, seeking natural and scientifically-backed dietary supplements to support cardiovascular health, improve blood flow, and benefit from antioxidant properties. They are often informed about the benefits of polyphenols and look for innovative wellness solutions.
- Aging Population: Individuals, typically in their middle to later years, who are concerned with age-related health challenges, particularly those affecting cardiovascular function, cognitive health, and overall vitality. They seek supplements that can help maintain healthy aging and improve quality of life.
- Early Adopters and Wellness Enthusiasts: Consumers who are open to trying new biotechnology-derived health products and are interested in cutting-edge nutritional science. This group often researches product efficacy and embraces innovative approaches to personal wellness.
AI Analysis | Feedback
AI Analysis | Feedback
Ilan Sobel, Chief Executive Officer
Ilan Sobel has been the CEO of BioHarvest Sciences since July 2020. Before joining BioHarvest, he spent six years at Weissbeerger as both Chief Operating Officer and Chief Commercial Officer, where he played a significant role in building a disruptive big data, IoT, and software company that was eventually acquired by Anheuser Busch InBev. Prior to Weissbeerger, Mr. Sobel held senior leadership positions for 18 years as an international employee of The Coca-Cola Company across various global markets. He initially became involved with BioHarvest as an investor before taking on the CEO role.
Bar Dichter, Chief Financial Officer
Bar Dichter was appointed Chief Financial Officer in October 2024. She joined BioHarvest in 2018 as Controller and was promoted to Vice President, Finance in July 2022. Before her tenure at BioHarvest, Ms. Dichter worked in the audit department of KPMG Israel.
Dr. Yochi Hagay, Chief Technology Officer
Dr. Yochi Hagay is a co-founder of BioHarvest Sciences, which was established in 2007. She previously served as both CEO and CTO of BioHarvest until 2017. Before co-founding the company, Dr. Hagay was the Managing Partner at Zaki Rakib's Bio-Tech Capital Venture, where she evaluated numerous scientific research projects and biotech companies. Her career also includes 15 years in various roles at BTG, until its acquisition by Savient. Dr. Hagay holds a PhD in biotechnology from Hebrew University.
Dr. Zaki Rakib, Chairman Of The Board / President, Botanical Synthesis CDMO Business Unit
Dr. Zaki Rakib co-founded BioHarvest in 2007. He serves as the Chairman of BioHarvest and President of the Botanical Synthesis CDMO Business Unit. Dr. Rakib has extensive experience across software, telecommunications hardware, semiconductors, cellular operations, and bioscience. He was also a co-founder of Terayon Communication Systems, a company credited with inventing the first cable modem and S-CDMA technology.
Dr. Ilana Belzer, Chief Operating Officer
Dr. Ilana Belzer brings extensive leadership and technical knowledge to her role as Chief Operating Officer. She previously held the position of COO at CollPlant Biotechnologies, a NASDAQ-listed company specializing in regenerative and aesthetics medicine. Prior to her time at CollPlant, Dr. Belzer served as COO at BioHarvest Ltd. from 2012 to 2015. She earned her Ph.D. in Microbiology and Cell Biology from Tel Aviv University.
AI Analysis | Feedback
Key Risks to BioHarvest Sciences (BHST)
- Commercialization, Market Acceptance, and Intense Competition: BioHarvest Sciences faces significant risks in successfully commercializing its products, such as VINIA, and securing contracts for its CDMO services in highly competitive markets. The nutraceutical market, in particular, is described as intense, with numerous competitors. Launching new products is subject to uncertainties regarding market acceptance, evolving consumer tastes, trends, and the company's ability to effectively market and distribute its offerings.
- Regulatory and Clinical Trial Risks: As a biotechnology company developing "science-based and clinically proven therapeutic solutions" in both nutraceuticals and pharmaceuticals, BioHarvest Sciences is exposed to substantial regulatory hurdles. Obtaining government approvals for the sale and import of products, particularly for pharmaceutical applications, is a lengthy, costly, and uncertain process. Failure in clinical trials or inability to secure necessary regulatory clearances could significantly delay or prevent product commercialization.
- Execution Risk of Proprietary Technology and Achieving Profitability: The company's business model is fundamentally reliant on its "botanical synthesis platform technology". There is a risk that this technology may not consistently and cost-effectively produce high-purity compounds at the required commercial scale, or that competitors may develop superior alternatives. Furthermore, BioHarvest Sciences has been operating at a net loss, with high expectations for achieving adjusted EBITDA breakeven in the near future (e.g., Q4 2025 or H2 2025). This financial execution risk, coupled with a relatively high debt level, creates pressure to meet aggressive growth and profitability milestones to justify its valuation and ensure long-term sustainability.
AI Analysis | Feedback
The rapid advancement and commercialization of alternative precision fermentation and cellular agriculture platforms. While BioHarvest Sciences leverages a plant cell-based botanical synthesis platform, other biotechnology companies are increasingly utilizing microbial (e.g., yeast, bacteria) or other non-plant cell lines to produce complex, high-value ingredients traditionally derived from plants. If these alternative platforms prove to be significantly more scalable, cost-effective, or versatile in producing the same or functionally similar complex phytochemicals (such as polyphenols, cannabinoids, or other therapeutic compounds BioHarvest aims to develop), they could directly undermine BioHarvest's competitive advantage in ingredient manufacturing and its contract development and manufacturing operation services.
AI Analysis | Feedback
BioHarvest Sciences Inc. (NASDAQ: BHST) operates in several key markets, with significant addressable opportunities in the global nutraceutical, pharmaceutical, and contract development and manufacturing organization (CDMO) sectors.
Nutraceuticals Market
BioHarvest Sciences' flagship product, VINIA, is a red grape cell dietary supplement rich in polyphenols, including Piceid Resveratrol. This product falls within the broader nutraceuticals and dietary supplements markets. The global nutraceuticals market was estimated at approximately USD 596.81 billion in 2025 and is projected to reach around USD 1,104.66 billion by 2033, demonstrating a compound annual growth rate (CAGR) of 8.00% from 2025 to 2033. Other estimates for the global nutraceuticals market size in 2025 range from USD 500.62 billion to USD 636.31 billion, with projections reaching between USD 1,124.56 billion and USD 1,328.63 billion by 2034 or 2035. Within this, the dietary supplements segment held the largest share in 2024 and is expected to be the fastest-growing category.
More specifically, the global polyphenol market, which includes ingredients like those found in VINIA, was valued at USD 2.12 billion in 2024. It is anticipated to grow to USD 3.65 billion by 2033, with a CAGR of 6.17% from 2025 to 2033. The dietary supplements application segment accounted for a significant portion, 32.96%, of the polyphenol market in 2025.
Pharmaceuticals Market
The company leverages its botanical synthesis platform to develop therapeutic solutions in the pharmaceuticals vertical. This aligns with the "Botanical and Plant-Derived Drugs Market." The global botanical and plant-derived drugs market is projected to grow from US$ 61.6 billion in 2025 to US$ 114.1 billion by 2032, at a CAGR of 9.2%. Another report estimates the global botanical drug market size at USD 41.85 billion in 2024, with an expected increase to USD 81.56 billion by 2034, growing at a CAGR of 6.9% during the forecast period of 2025 to 2034.
Furthermore, BioHarvest's botanical synthesis technology also contributes to the "plant-based API (Active Pharmaceutical Ingredient) market." This global market was estimated at USD 31.78 billion in 2024 and is projected to reach USD 53.21 billion by 2033, exhibiting a CAGR of 5.9% from 2025 to 2033. The pharmaceuticals segment alone held the largest revenue share in the plant-based API market, accounting for 63.29% in 2024.
Contract Development and Manufacturing Organization (CDMO) Services Market
BioHarvest Sciences also provides contract development and manufacturing operation services. The global pharmaceutical CDMO market size is substantial, with estimates placing it at approximately USD 197.40 billion in 2025. This market is projected to grow to USD 368.70 billion by 2034, at a healthy CAGR of 7.2% from 2024 to 2034. Other analyses indicate the global CDMO market to be around USD 220 billion in 2025, with projections reaching USD 420 billion by 2032-2034, growing at a 7.5% CAGR.
AI Analysis | Feedback
BioHarvest Sciences Inc. (NASDAQ: BHST) is expected to drive future revenue growth over the next 2-3 years through several key initiatives:
- Continued Growth of VINIA® Direct-to-Consumer Business: The company anticipates significant revenue growth from its flagship red grape cell-derived VINIA® line by expanding its direct-to-consumer business and increasing its subscriber base. Management has indicated expectations for continued substantial growth in this segment, building on a track record of doubling this business annually for the past three years.
- Expansion of "VINIA Inside" Strategy and New Product Launches: BioHarvest Sciences plans to leverage its VINIA® technology into new product categories. This includes the launch and scaling of its VINIA® SuperFood Coffee and SuperFood Tea lines, with K-cup compatible versions introduced in early 2025. Additionally, the company launched VINIA® Daily Chews 2X Formula in August 2025, and intends to enter the U.S. hydration solution and athlete supplement markets with VINIA® products by 2026.
- Growth in Contract Development and Manufacturing Organization (CDMO) Services: The CDMO division is poised for substantial growth through securing new contracts and advancing existing projects from Phase 1 to Phase 2. The company announced a new Stage 1 CDMO contract for a plant-based fragrance compound in Q2 2025 and a partnership with Tate & Lyle to develop plant-based sweeteners. BioHarvest also expects to identify new plant-based biological compounds using AI-enabled discovery tools, further expanding its CDMO revenue streams.
- Launch of "Health Pros" Professional Affiliate Program: Introduced in the second half of 2025, this program aims to broaden VINIA®'s market reach and enhance subscriber acquisition efficiency. It involves establishing a network of health practitioners, athletes, coaches, and health influencers who can promote VINIA® products to their significant social media followings.
AI Analysis | Feedback
Share Issuance
- In August 2021, BioHarvest Sciences announced a private placement for up to CAD 4 million through the issuance of units, which included common shares and warrants, to accelerate its cannabis development program and production capacity in Israel.
- In April 2022, the company announced a private placement of up to USD $5 million (approximately CAD $6.3 million) in convertible notes to finance production facilities and scale its polyphenols/antioxidants and cannabis verticals.
- In November 2025, BioHarvest Sciences completed an underwritten public offering of 2,846,854 shares of common stock at $7.00 per share, generating gross proceeds of $19.9 million, including shares issued upon the exercise of the underwriters' option to purchase additional shares. The net proceeds from this offering are designated for immediate funding of additional manufacturing expansion, research and development, marketing, debt reduction or refinancing, other capital expenditures, and general corporate purposes.
Inbound Investments
- In December 2025, BioHarvest Sciences was awarded a $1.6 million USD grant from the Israeli Innovation Authority (IIA) under its Bio-Convergence program, providing non-dilutive funding to advance its second-generation Botanical Synthesis™ process through AI integration, increased bioreactor size, and expanded autonomous manufacturing functions.
Capital Expenditures
- Funds from a CAD 4 million private placement in August 2021 were allocated for system upgrades to convert the existing 2 tons/year VINIA® facility into a cannabis production facility, expected to be operational in the first half of 2022.
- A new facility capable of producing 100 tons per year is planned to be operational by late 2026, quadrupling the company's current output and including strategic investments in an 80,000 square foot corporate campus in Yavneh, Israel.
- As of January 2026, the company is fully funded for near-term capital expenditures, enabling investments in scale, efficiency, and margin expansion, including the planned development of a 100-ton manufacturing footprint at its corporate campus to support both direct-to-consumer growth and future CDMO production.
Peer Outperformance in Packaged Foods & Meats
| Industry | Names | 1Y med | 3Y med | 5Y med | Top 3 by 5Y |
|---|---|---|---|---|---|
| Consumer Staples Merchandise Retail | 12 | 12.9% | 45.0% | 49.5% | NGVC 179% · VLGEA 135% · WMT 129% |
| Tobacco | 6 | -23.3% | 19.9% | 35.8% | PM 117% · MO 99% · TPB 50% |
| Food Retail | 6 | -11.7% | 73.0% | 30.0% | CASY 276% · SFM 232% · KR 40% |
| Food Distributors | 9 | -0.2% | 40.3% | 18.1% | CHEF 294% · USFD 214% · ANDE 151% |
| Soft Drinks & Non-alcoholic Beverages | 12 | -6.0% | -11.9% | 5.3% | COKE 398% · BRFH 202% · CCHGY 109% |
| Brewers | 3 | -14.4% | -27.6% | 1.7% | BUD 44% · TAP 2% · SAM -70% |
| Agricultural Products & Services | 11 | 2.4% | 6.0% | -11.5% | BG 75% · ADM 62% · INGR 32% |
| Household Products | 19 | 1.2% | -8.1% | -23.3% | IPAR 76% · ACU 69% · CL 28% |
| Personal Care Products | 4 | -5.3% | -19.5% | -25.8% | ELF 258% · PG 16% · EL -67% |
| Packaged Foods & Meats ← | 47 | -23.3% | -31.8% | -39.5% | MAMA 466% · LWAY 363% · SENEA 302% |
| Distillers & Vintners | 5 | -41.3% | -58.9% | -74.9% | STZ -34% · BF-B -58% · MGPI -75% |
| Drug Retail | 3 | -40.5% | -83.8% | -92.7% | HITI -66% · PETS -93% · SCNX -99% |
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Can BioHarvest Sciences Stock Recover If Markets Fall? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 10.48 |
| Mkt Cap | 0.3 |
| Rev LTM | 272 |
| Op Inc LTM | -15 |
| FCF LTM | -11 |
| FCF 3Y Avg | -26 |
| CFO LTM | -9 |
| CFO 3Y Avg | -23 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 12.1% |
| Rev Chg 3Y Avg | 1.6% |
| Rev Chg Q | -0.4% |
| QoQ Delta Rev Chg LTM | -0.0% |
| Op Inc Chg LTM | 8.0% |
| Op Inc Chg 3Y Avg | 17.3% |
| Op Mgn LTM | -24.6% |
| Op Mgn 3Y Avg | -36.2% |
| QoQ Delta Op Mgn LTM | -0.3% |
| CFO/Rev LTM | -12.8% |
| CFO/Rev 3Y Avg | -21.9% |
| FCF/Rev LTM | -18.6% |
| FCF/Rev 3Y Avg | -29.1% |
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Products | 33 | 25 | 13 | ||
| Contract Development and Manufacturing Operation (CDMO) Services | 2 | 0 | 0 | ||
| Nutraceuticals | 5 | 2 | |||
| Pharmaceuticals | 0 | 0 | |||
| Total | 35 | 25 | 13 | 5 | 2 |
| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Contract Development and Manufacturing Operation (CDMO) Services | -0 | -1 | 0 | ||
| Products | -5 | -6 | -10 | ||
| Nutraceuticals | -7 | -4 | |||
| Pharmaceuticals | -3 | -4 | |||
| Total | -6 | -7 | -10 | -11 | -8 |
| $ Mil | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|
| Pharmaceuticals | 24 | 18 | ||
| Nutraceuticals | 10 | 10 | ||
| Adjustment & Elimination | -24 | -17 | -6 | |
| Cannabis | 5 | |||
| Superfruits | 6 | |||
| Single segment | 6 | |||
| Total | 9 | 10 | 5 | 6 |
Price Behavior
| Market Price | $1.82 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 03/08/2019 | |
| Distance from 52W High | -85.6% | |
| 50 Days | 200 Days | |
| DMA Price | $2.43 | $4.06 |
| DMA Trend | down | down |
| Distance from DMA | -25.2% | -55.2% |
| 3M | 1YR | |
| Volatility | 72.7% | 77.2% |
| Downside Capture | 170.96 | 159.95 |
| Upside Capture | -118.60 | -39.43 |
| Correlation (SPY) | 0.8% | 16.1% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.06 | -0.55 | 0.11 | 0.36 | 1.05 | 0.61 |
| Up Beta | 2.15 | -0.60 | 1.91 | 1.47 | 2.12 | 0.77 |
| Down Beta | -6.14 | -1.64 | -1.20 | -0.59 | 1.11 | 0.72 |
| Up Capture | -105% | -152% | -126% | -51% | -19% | 5% |
| Bmk +ve Days | 10 | 21 | 32 | 68 | 138 | 427 |
| Stock +ve Days | 8 | 18 | 26 | 49 | 98 | 324 |
| Down Capture | 138% | 179% | 165% | 132% | 139% | 86% |
| Bmk -ve Days | 11 | 21 | 32 | 59 | 113 | 324 |
| Stock -ve Days | 10 | 21 | 34 | 70 | 145 | 364 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with BHST | |
|---|---|---|---|---|
| BHST | -76.2% | 77.2% | -1.52 | - |
| Sector ETF (XLP) | 7.1% | 14.4% | 0.25 | 2.6% |
| Equity (SPY) | 19.7% | 12.8% | 1.13 | 16.4% |
| Gold (GLD) | 24.6% | 29.2% | 0.75 | 11.6% |
| Commodities (DBC) | 44.1% | 20.4% | 1.69 | -0.6% |
| Real Estate (VNQ) | 9.1% | 13.6% | 0.39 | -2.2% |
| Bitcoin (BTCUSD) | -26.9% | 43.8% | -0.59 | 16.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with BHST | |
|---|---|---|---|---|
| BHST | -26.7% | 76.1% | -0.10 | - |
| Sector ETF (XLP) | 6.0% | 13.7% | 0.22 | 7.4% |
| Equity (SPY) | 12.8% | 17.2% | 0.57 | 14.9% |
| Gold (GLD) | 19.1% | 18.8% | 0.82 | 5.5% |
| Commodities (DBC) | 10.7% | 19.5% | 0.43 | 3.8% |
| Real Estate (VNQ) | 1.7% | 18.9% | -0.01 | 10.1% |
| Bitcoin (BTCUSD) | 10.6% | 52.6% | 0.38 | 5.6% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with BHST | |
|---|---|---|---|---|
| BHST | -19.6% | 97.1% | 0.11 | - |
| Sector ETF (XLP) | 7.2% | 14.9% | 0.35 | 5.6% |
| Equity (SPY) | 15.3% | 17.9% | 0.72 | 10.8% |
| Gold (GLD) | 12.4% | 16.3% | 0.62 | 3.5% |
| Commodities (DBC) | 7.9% | 18.1% | 0.35 | 2.2% |
| Real Estate (VNQ) | 4.8% | 20.7% | 0.19 | 7.9% |
| Bitcoin (BTCUSD) | 64.0% | 66.2% | 1.04 | 7.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 6/3/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| SUMMARY STATS | |||
| # Positive | 0 | 0 | 0 |
| # Negative | 0 | 0 | 0 |
| Median Positive | |||
| Median Negative | |||
| Max Positive | |||
| Max Negative | |||
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| SUMMARY STATS | |||
| # Positive | 0 | 0 | 0 |
| # Negative | 0 | 0 | 0 |
| Median Positive | |||
| Median Negative | |||
| Max Positive | |||
| Max Negative | |||
BioHarvest Sciences — Investor Video Playlist
Industry Resources
| Consumer Staples Resources |
| FoodNavigator |
| Consumer Goods Technology (CGT) |
| Beverage Digest |
| Packaged Foods & Meats Resources |
| USDA Data |
| Food Processing |
| Meat+Poultry |
| Just Food |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.